Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.44 USD | +9.51% | +9.12% | -24.24% |
15/04 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
25/03 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- NTLA Stock
- Revisions Intellia Therapeutics, Inc.